Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023)
Background: Although Namibia started implementing pre-exposure prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-10-01
|
| Series: | Journal of Infection and Public Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1876034122002398 |
| _version_ | 1798000265537781760 |
|---|---|
| author | Enos Moyo Leela Barham Malizgani Mhango Godfrey Musuka Tafadzwa Dzinamarira |
| author_facet | Enos Moyo Leela Barham Malizgani Mhango Godfrey Musuka Tafadzwa Dzinamarira |
| author_sort | Enos Moyo |
| collection | DOAJ |
| description | Background: Although Namibia started implementing pre-exposure prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV for all eligible people in the public health sector in Namibia from 2021 to 2023. Methods: A country-specific model was developed for this budget impact analysis (BIA). PrEP has targeted all eligible people in Namibia who receive health services from the public sector. It was assumed that the adherence rate was 75% and PrEP effectiveness 60% in this study. Costs used in this study were taken from a study that included Namibian costs. Results: The BIA suggests that adopting PrEP may be cost saving as US$104 823, US$143 620, and US$182 452 of additional HIV care costs will potentially be saved in 2021, 2022, and 2023, respectively. Cost savings rely on high adherence rates, high PrEP effectiveness rates, low PrEP costs, and a small number of people living with HIV (PLHIV). Conclusion: Further economic analysis could aid decision-making in Namibia, both to stress test assumptions in the BIA and conduct cost-effectiveness analysis to estimate the value for money of PrEP. |
| first_indexed | 2024-04-11T11:16:59Z |
| format | Article |
| id | doaj.art-92aefe7de281435b9d0b0a3d634f5d5b |
| institution | Directory Open Access Journal |
| issn | 1876-0341 |
| language | English |
| last_indexed | 2024-04-11T11:16:59Z |
| publishDate | 2022-10-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Infection and Public Health |
| spelling | doaj.art-92aefe7de281435b9d0b0a3d634f5d5b2022-12-22T04:27:11ZengElsevierJournal of Infection and Public Health1876-03412022-10-01151011471155Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023)Enos Moyo0Leela Barham1Malizgani Mhango2Godfrey Musuka3Tafadzwa Dzinamarira4University of South Wales, UKFaculty of Life Science and Education, Learna, Cardiff CF14 5GF, Wales, UKSchool of Public Health, University of Western Cape, 7535 Cape Town, South AfricaICAP at Columbia University, Harare, ZimbabweSchool of Health Systems & Public Health, University of Pretoria, Pretoria 0002, South Africa; Corresponding author.Background: Although Namibia started implementing pre-exposure prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV for all eligible people in the public health sector in Namibia from 2021 to 2023. Methods: A country-specific model was developed for this budget impact analysis (BIA). PrEP has targeted all eligible people in Namibia who receive health services from the public sector. It was assumed that the adherence rate was 75% and PrEP effectiveness 60% in this study. Costs used in this study were taken from a study that included Namibian costs. Results: The BIA suggests that adopting PrEP may be cost saving as US$104 823, US$143 620, and US$182 452 of additional HIV care costs will potentially be saved in 2021, 2022, and 2023, respectively. Cost savings rely on high adherence rates, high PrEP effectiveness rates, low PrEP costs, and a small number of people living with HIV (PLHIV). Conclusion: Further economic analysis could aid decision-making in Namibia, both to stress test assumptions in the BIA and conduct cost-effectiveness analysis to estimate the value for money of PrEP.http://www.sciencedirect.com/science/article/pii/S1876034122002398Budget impact analysisHIVPrEPNamibiaTenofovir/emtricitabine |
| spellingShingle | Enos Moyo Leela Barham Malizgani Mhango Godfrey Musuka Tafadzwa Dzinamarira Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) Journal of Infection and Public Health Budget impact analysis HIV PrEP Namibia Tenofovir/emtricitabine |
| title | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) |
| title_full | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) |
| title_fullStr | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) |
| title_full_unstemmed | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) |
| title_short | Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023) |
| title_sort | estimating the budget impact of adopting tenofovir emtricitabine for pre exposure prophylaxis of hiv in the public health sector in namibia 2021 2023 |
| topic | Budget impact analysis HIV PrEP Namibia Tenofovir/emtricitabine |
| url | http://www.sciencedirect.com/science/article/pii/S1876034122002398 |
| work_keys_str_mv | AT enosmoyo estimatingthebudgetimpactofadoptingtenofoviremtricitabineforpreexposureprophylaxisofhivinthepublichealthsectorinnamibia20212023 AT leelabarham estimatingthebudgetimpactofadoptingtenofoviremtricitabineforpreexposureprophylaxisofhivinthepublichealthsectorinnamibia20212023 AT malizganimhango estimatingthebudgetimpactofadoptingtenofoviremtricitabineforpreexposureprophylaxisofhivinthepublichealthsectorinnamibia20212023 AT godfreymusuka estimatingthebudgetimpactofadoptingtenofoviremtricitabineforpreexposureprophylaxisofhivinthepublichealthsectorinnamibia20212023 AT tafadzwadzinamarira estimatingthebudgetimpactofadoptingtenofoviremtricitabineforpreexposureprophylaxisofhivinthepublichealthsectorinnamibia20212023 |